Carcinoma of the oral pharynx: an analysis of subsite treatment heterogeneity

Surg Oncol Clin N Am. 2004 Jan;13(1):71-80. doi: 10.1016/S1055-3207(03)00117-0.

Abstract

The data indicate that SCC of the various subsites of the oropharynx can be treated successfully with acceptable locoregional control and survival rates by using either surgery or primary radiotherapy for TI or T2 primary lesions. Treatment success data for late-stage disease (T3 and T4) are less encouraging. regardless of which modality is used or which treatment center is administering treatment. This finding may suggest an intrinsic property of these lesions or the patient that may be going unnoticed.One problem is that the diversity of approaches to these lesions hinders any meaningful comparisons between series from different treatment centers. There exists heterogeneity in patient populations and approaches to staging and characterization of these diseases. This situation has ensured the same heterogeneity in treatment philosophy, which is largely institutionally based.

Publication types

  • Review

MeSH terms

  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / surgery*
  • Combined Modality Therapy
  • Head and Neck Neoplasms / diagnosis
  • Head and Neck Neoplasms / mortality
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / surgery*
  • Humans
  • Lymphatic Metastasis
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / therapy
  • Palatal Neoplasms / pathology
  • Palatal Neoplasms / therapy
  • Palate, Soft / pathology
  • Pharyngeal Neoplasms / pathology
  • Pharyngeal Neoplasms / therapy
  • Prognosis
  • Tongue Neoplasms / pathology
  • Tongue Neoplasms / therapy
  • Tonsillar Neoplasms / pathology
  • Tonsillar Neoplasms / therapy